Nanoformulations of natural products for management of metabolic syndrome

Yasamin Davatgaran Taghipour1–3
Marziyeh Hajalyani4
Rozita Naseri5
Mahvash Hesari6
Pantea Mohammadi6
Azzurra Stefanucci7
Adriano Mollica7
Mohammad Hosein Farzaei4,6
Mohammad Abdollahi8
1Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;
2Phytopharmacology Interest Group (PPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran;
3Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;
4Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran;
5Internal Medicine Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran;
6Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;
7Department of Pharmacy, G. d’Annunzio University of Chieti-pescara, Chieti 66100, Italy;
8Toxicology and Diseases Group, the Institute of Pharmaceutical Sciences (TIPS) and Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Correspondence: Mohammad Hosein Farzaei
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Tel +98 833 825 0271
Email mh.farzaei@gmail.com

Mohammad Abdollahi
Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS) and Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran 1417614411, Iran
Tel +98 912 171 0860
Email Mohammad@TUMS.Ac.Ir

Abstract: Metabolic syndrome is a common metabolic disorder which has become a public health challenge worldwide. There has been growing interest in medications including natural products as complementary or alternative choices for common chemical therapeutics regarding their limited side effects and ease of access. Nanosizing these compounds may help to increase their solubility, bioavailability, and promisingly enhance their efficacy. This study, for the first time, provides a comprehensive overview of the application of natural-products-based nanoformulations in the management of metabolic syndrome. Different phytochemicals including curcumin, berberine, Capsicum oleoresin, naringenin, emodin, gymnemic acid, resveratrol, quercetin, scutellaran, stevioside, silybin, baicalin, and others have been nanosized hitherto, and their nanosizing method and effect in treatment and alleviating metabolic syndrome have been reviewed and discussed in this study. It has been discovered that there are several pathways or molecular targets relevant to metabolic disorders which are affected by these compounds. Various natural-based nanoformulations have shown promising effect in treatment of metabolic syndrome, and therefore can be considered as future candidates instead of or in conjunction with pharmaceutical drugs if they pass clinical trials successfully.

Keywords: nanoformulation, natural products, metabolic syndrome, diabetes

Introduction

Metabolic syndrome (MetS) is a health disorder that includes a cluster of medical conditions occurring together. MetS increases the risk of progressing atherosclerotic cardiovascular diseases (CVDs), central obesity, insulin resistance, systemic hypertension, cerebrovascular accident, and atherogenic dyslipidemia.1,2 Diverse definition has been suggested by the International Diabetes Federation, National Cholesterol Education Program’s Adult Treatment Panel III, and the WHO. All mentioned international agencies concentrate on five medical conditions as a diagnosis guideline which include waist circumference more than 35 inches in women and 40 inches in men, enhanced fasting glucose of 100 mg/dL or greater, increased triglycerides (TGs) 150 mg/dL or greater, declined high-density lipoprotein cholesterol (HDL) less than 50 mg/dL in women and less than 40 mg/dL in men, and blood pressure values of systolic 130 mmHg or higher and/or diastolic 85 mmHg or higher.3 Chronic inflammation has been associated with insulin resistance and visceral obesity, which results in creation of abnormal adipocytokines including IL-1, IL-6, TNF-α, adiponectin, and leptin.4 In the case of MetS, lifestyle modification should be included along with pharmacological treatment for those who have high levels of risk factors. An ordinary treatment guideline for MetS consists of prescribing drugs to lower the blood glucose level, TGs, and...
blood pressure along with improvement of the patient’s lifestyle. Treatment with common medications exerts unpleasant adverse effects such as flatulence and other related side effects in the early stage of treatment. This high level of adverse effects leads to a weak tolerance of the patient especially in the long-term application of the medications. In order to decrease side effects of these medications and to improve the efficiency of drug delivery for treatment of MetS, nanoformulation of natural and synthetic agents is an option. Nanosized drug carriers, consisting of phytochemicals from conventional medicines endowed with developed pharmacodynamics and pharmacokinetic characteristics, are a novel therapeutic approach. The nano-vehicles provide unique properties including enhanced bioavailability and solubility of the drug, diminished systemic adverse effects, elongated circulation time, and privileged accumulation in the precise target organ. Therefore, different phytochemicals including curcumin, berberine (BBR), oleoresin capiscum, naringenin, emodin, gymnemic acid, resveratrol, quercetin (QUE), scutellarin, stevioside, silybin, baicalin, and others have been used in diverse strategies for treatment and alleviation of MetS. These phytochemicals have been incorporated into diverse nanoformulation structures including polymeric-based polyesters, polyanhydride, poly (alkyl cyanoacrylate), etc, and natural ones (including cellulose, collagen, albumin, chitosan, dextran, etc). Lipid-based drug delivery systems such as micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers, and other related nanoformulations have also been included. Each polymeric and lipid nanostructure has precise synthesis and drug loading methods and have been described in this review.

Pathophysiology of MetS

Increasing knowledge about the exact pathophysiology of MetS is very necessary to succeed in the design of suitable medicines and pharmaceutical forms. Among different cellular pathways suggested, insulin resistance and excess fatty acid are the most widely accepted ones. Insulin promotes glucose uptake in the main target tissues of the liver, skeletal muscle, and adipocytes via glycoprotein receptors and inhibiting lipolysis and hepatic gluconeogenesis. Activation of the insulin receptor initiates a cascade of phosphorylation events using substrates which comprise insulin receptor substrates (IRS-1–IRS-4) as well as JAK-2, which are docking proteins that activate numerous signaling cascades. The pathways for this activating process are PI3K/PKB, known as Akt signaling. This process contributes to various metabolic activities of insulin and the MAPK signaling cascade that controls the regular function and growth of cells. Insulin-dependent glucose cellular uptake is activated by migration of GLUT4 from an intracellular compartment to the plasma membrane. GLUT4 is highly expressed in skeletal muscles and adipose tissues. Glucose is then phosphorylated as the substrate for glycogen synthesis or can be metabolized to adenosine triphosphate. Frequent stroke and heart failure propose a probable relation between this pathophysiological condition and CVDs. Changes in the levels of insulin signaling proteins like Glut4, IR-β, PI3K, IRS-1, PGC-1α, and Akt, are involved in blocking insulin-mediated glucose uptake along with other insulin functions in the cardiomyocytes.

Insulin resistance is the most widely accepted hypothesis for underlying pathophysiology of MetS. Free fatty acids (FFAs) inhibit protein kinase activity and reduce glucose uptake in the muscle, but in the liver – with increment of protein kinase activity – result in production of atherogenic factors such as glucose, TGs, and low-density lipoprotein (LDL). In response to hyperglycemia, beta cells release more insulin to maintain euglycemia which results in hyperinsulinemia. Ultimately, failure in compensation and consequently reduction of insulin secretion occurs. FFAs can induce lipotoxicity in pancreatic beta cells, causing reduction of insulin secretion. Reduced responsiveness to normal insulin level causes type 2 diabetes and contributes to the development of hypertension because of disturbance in the vasodilator effect of insulin.

Dyslipidemia

Dyslipidemia refers to unhealthy levels of one or more kinds of lipids in blood, increased levels of apo B, TGs, LDL, with reduced level of HDL, resulting from several abnormalities in structure, metabolism, and biology of atherogenic and antiatherogenic lipoproteins. Dyslipidemia is often due to diet and lifestyle, but prolonged elevation of insulin level can also lead to atherogenic dyslipidemia via different pathways. Firstly, insulin inhibits lipolysis, thus this disturbance in insulin signaling enhances lipolysis which can cause production of FFAs. In the hepatocytes, FFAs act as a substrate for the synthesis of TGs resulting in enhancement of very-low-density lipoprotein (VLDL) production. Next, insulin participates in apoB degradation and lipoprotein lipase activity, so in this case, hypertriglyceridemia could be attributed to increase in VLDL production and reduction of its clearance. CETP collects TGs from VLDL or LDL and exchanges
them for cholesteryl esters which leads to TG-enriched HDL. Hepatic lipase can rapidly clear HDL particles rich in TGs and remove them from the circulation.  

**Hypertension**

Obesity is the main factor for insulin resistance with consequent hyperinsulinemia. Type 2 diabetes and a genetic predisposition with a family history of hypertension are other important risk factors for hyperinsulinemia. There are accumulating data indicating angiotensin II’s inhibitory effect on insulin action. In fact, in vascular muscle tissues, angiotensin II interferes with insulin signaling through PI3K and its downstream Akt signaling pathway. This angiotensin II inhibitory effect is performed via stimulation of RhoA activity. Increased levels of RhoA activity and ROS inhibit PI3K/Akt signaling followed by a decrease in production of NO within endothelial cells and consequently increased vasoconstriction. Activated renin-angiotensin system may contribute to development of hypertension in MetS. On the other hand, in obese individuals, a probable shift from PI3K to the MAPK pathway can cause pro-atherogenic function. Hyperinsulinemia also increases re-absorption of sodium in the kidneys through activation of sympathetic nervous system, improving the cardiac output and vasoconstriction of arteries, which will all lead to hypertension.

**Inflammatory and oxidative mediators**

Adipose tissue is a dynamic endocrine organ able to release a number of bioactive peptides including adiponectin, IL-6 (by increasing CRP production), resistin, RBP4, leptin, and TNF-α. Dysregulation of adipose tissue activity has been implicated in over-secretion of deleterious adipokines and hypo-secretion of beneficial ones. Leptin has a major role in the regulation of metabolism of the entire body by stimulating energy expenditure, preventing food intake, and restoring euglycemia. However, in the majority of obesity cases, resistance of leptin limits its biological efficacy. In contrast to leptin, secretion of adiponectin is often decreased in obesity. Adiponectin is directly associated with an increase of insulin sensitivity, enhancement of fatty acid oxidation, and decrease in the production of glucose by the liver.

**Natural compounds and medicinal plants for treatment of MetS**

It has been shown that natural products or their derivatives are a valuable source of therapeutic agents. Consistent with this approach, researchers have focused on natural products in the field of prevention or treatment of MetS. MetS increases the risk of both atherosclerotic and non-atherosclerotic CVD, one of the leading causes of death in the world. Results from a meta-analysis showed that MetS increases the risk of CVD outcomes and mortality. Considering the morbidity and mortality caused by MetS and cardiometabolic disorders, there is a high interest in the discovery of novel compounds and pharmacological targets that might be effective in the prevention or treatment of metabolic and/or cardiovascular disorders. Many medicinal plants and natural products are considered by the public as a safe and natural alternative to synthetic drugs, of course without definite proof from randomized controlled clinical trials. Therefore, there is an increased interest in development of products with validated efficacy and safety.

**Major pharmacological targets of natural compounds involved in prevention of MetS**

Different molecular mechanisms have been reported for therapeutic activity of natural products against cardiovascular disorders and Mets. DPP-4, COX-1 and -2, AMPK, PTP1B, transcription factors NF-κB, Nrf2, PPARs, eNOS, and 5-LO are involved in anti-inflammatory activity, amelioration of blood lipid profiles, normalization of blood glucose levels, improvement of insulin sensitivity and transcriptional regulation of genes controlling lipid metabolism. Recently, PPARs and some other nuclear receptors have been under focus of scientists due to their regulatory roles in homeostasis of glucose, metabolism of lipids and lipoproteins, cellular proliferation, cellular differentiation, and cellular apoptosis. PPARs are a group of steroid/thyroid nuclear receptor superfamilies of ligand-activated transcription factors. PPAR subfamily includes alpha-, beta-, and gamma-subtypes which are activators of key metabolic pathways and highly expressed in tissues relevant to energy homeostasis. PPARs also possess a prominent role in differentiation of adipocyte and insulin sensitivity. PPAR-α involves fatty acid catabolism whereas PPAR-β affects homeostasis of glucose, storage of lipids, and differentiation of adipocytes. The exact function of PPAR-β is less known hitherto. There is a progressive trend in identifying potent, biologically active agents for modulating nuclear receptors such as PPARs, LXR, and FXR. The most active PPAR agonists and combination agonists have been examined for treatment of type 2 diabetes and MetS.
Bitter Chinese tree *Pseudolarix kaempferi*, Gordon and Korean ginseng, *Panax ginseng* are two plants that possess PPAR-α modulatory activity. Pseudolaric acid B isolated from the bark of *P. kaempferi* is an efficient compound that induces maximum luciferase response with activation of PPAR-α in H4IIEC3 cells. In the case of ginseng, ginsenosides have been shown to have an inhibitory effect on PPAR-α, and thus have hypolipidemic effects.\(^{55,56}\)

Many PPAR-γ modulators have been detected such as Saururus A, an acyclic furanoditerpene constitute of *Saururus chinensis* (Saururaceae), and Genistein, a soy phyto-oestrogen compound, as PPAR-γ activators.\(^{59}\)

Other herbal-derived transcriptional modulators are LXRs, and FXR modulators.\(^{54,60}\) It has been reported that paxilline, a secondary metabolite of *Penicillium pixillii*, activates LXR.\(^{51}\)

FXR (NR1H4), known as BAR, is a nuclear receptor involved in regulation of genes in synthesis of bile acid, metabolism of lipoprotein, transport, and absorption.\(^{62}\) An ethyl acetate extract of the gum resin of *Commiphoramukul* decreased the level of LDL cholesterol and TGs in humans with an inhibitory effect on NR1H4.\(^{63}\)

### Natural product-based nanoformulations for MetS

Here, we refer to the most relevant nanoformulation of natural products which can be applied in prevention or alleviation of MetS. The advantages of nanoformulations vs conventional formulations are their greater surface area to volume ratio, targeted drug delivery, sustained and controlled drug release, and modified bioavailability. The disadvantages of nanoformulations compared with conventional formulations are short shelf-life, unforeseeable stability, pharmacokinetics, toxicity, and also being more expensive.\(^{64}\)

Therefore, nanoformulation methods and nanonization are offered as promising substitutions for conventional drug delivery systems. A brief report of the outcomes of administration of these natural-based nanodrugs in different models of MetS has been prepared in Table 1.

### Curcumin

Curcumin, a derivative of turmeric (*Curcuma longa*), belongs to the curcuminoid subgroup of polyphenols with a panel of pharmacological activities such as antitumor, antioxidant, anti-inflammatory, hypolipidemic, and anticarcinogenic effects.\(^{64,66}\) Many researchers have demonstrated that curcumin possesses therapeutic effects regarding MetS. Curcumin has been reported to suppress PAI-1 expression, activate Nrf2, downregulate TNF-α expression, and suppress NF-kB activation. In addition, it inhibits the obesity-related Wnt/β-catenin pathway, and activates PPAR-β in hepatic stellate cells.\(^{67-70}\) Curcumin also interrupts leptin signaling, thus increasing adiponectin expression. Curcumin negatively affects obesity and positively affects insulin sensitization, blunt the inflammatory pathways in MetS.\(^{20}\) It improves obesity-associated metabolic disorders such as hyperglycemia, hyperlipidemia, and insulin resistance. It also prevents LDL cholesterol oxidation and reduces body weight gain.\(^{71}\)

Clinical trials which have been performed for curcumin support its positive effects as an adjuvant therapy of type 2 diabetes.\(^{1,72,73}\) The poor water solubility of curcumin is a problem that should be resolved.\(^{74,75}\) Several strategies have been designed to cope with this problem, mostly including formulating this phytochemical in a nanosized structure.\(^{76}\) Encapsulation of curcumin in multipolymer poly (gamma-benzyl l-glutamate)-poly (ethylene glycol)-poly (gammabenzyl l-glutamate) nanoparticles (NPs) was a promising way to improve its bioactivity and water solubility. Such nanoformulation exerted a potent effect on relieving diabetic cardiomyopathy (DCM). DCM alters the systolic and/or diastolic cardiac functions which results in heart failure and myocardial ischemia. Curcumin encapsulated in multipolymer affects DCM and cross-regulates the receptors responsible for sensing calcium and endogenous CSE/hydrogen sulfide (H\(_2\)S). Continuous administration of this nanoformulation relieved pathological morphological destruction of myocardium, boosted serum levels of H\(_2\)S and ([Ca\(^{2+}\)])i content in myocardial cells, and upregulated the expression of CSE, CaSR, and CaM. The presence of curcumin in the structure of the nanoformulation can be the possible reason for such advantageous effects.\(^{77}\)

Self-emulsifying drug delivery system (SEDDS) has become important as a new approach to modify the dissolution, oral absorption, and solubility of drugs that are poorly soluble in water. SNEDDS is a branch of SEDDS which contains an isotropic mixture of drug substance, surfactant, co-surfactant, and oil, resulting in the formation of a nanocapsule just after consumption in the gastrointestinal tract. SNEDDS based on a curcumin formulation has been developed for alleviating diabetic neuropathy and found to be an efficient tool for relieving neuroinflammation, and modifying antioxidant defense in diabetic neuropathy.\(^{78}\) In another study, curcin-encapsulated NPs in Poly (lactic-co-glycolic acid)-Polyvinyl alcohol polymers were synthesized and it was studied in the streptozotocin (STZ)-induced diabetes cataract model. The average particle size was 282±5.72 nm with...
Table 1 Phytochemical-based nanoformulations for management of metabolic syndrome (MetS)

<table>
<thead>
<tr>
<th>Phytochemical</th>
<th>Nanoformulation</th>
<th>Disorder</th>
<th>Cellular/animal model</th>
<th>Dose</th>
<th>Size</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curcumin</td>
<td>PBLG-PEG-PBLG</td>
<td>Diabetic cardiomyopathy</td>
<td>Diabetic rats and H9C2 cells</td>
<td>20 mg/kg</td>
<td>30 nm</td>
<td>↑H₂S, ↑CaSR, ↑CSE, ↑CaM</td>
<td>77</td>
</tr>
<tr>
<td>CNPs @GMs/ hydrogel</td>
<td>Diabetic wound</td>
<td>STZ-induced diabetic rats</td>
<td>4 to 8 µm</td>
<td>↑GSH</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNEDDS</td>
<td>Diabetic neuropathy</td>
<td>STZ-induced diabetic rats</td>
<td>66.7 mg/kg</td>
<td>170 nm</td>
<td>↓TNF-α, ↓IL-6</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>PLGA-PVA polymers</td>
<td>Diabetic cataract</td>
<td>STZ-induced diabetic cataract model</td>
<td>2 mg/day</td>
<td>282±5.72 nm</td>
<td>↑VEGF, ↑cellular uptake, bioavailability</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>Pluronic nanomicelles</td>
<td>STZ-induced diabetes</td>
<td>STZ-induced diabetic rats</td>
<td>100 mg/kg</td>
<td>333±6 nm</td>
<td>↓Pdx-1 and NKx6.1</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>PLGA-based NPs with Q10</td>
<td>Diabetes complications</td>
<td>STZ-induced diabetic rats</td>
<td>100 mg/kg</td>
<td>237±6 nm</td>
<td>↓CRP, IL-6, total cholesterol, ↓plasma triglycerides, ↓HDL</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Curcumin nanoemulsion</td>
<td>Hypertension and hypercholesterolemia</td>
<td>In vitro study</td>
<td>42.93±29.85 nm</td>
<td>Inhibition of HMGR along with ACE</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEGMA-DMAEMA-MAO</td>
<td>Diabetic peripheral neuropathy</td>
<td>STZ-induced diabetic rats</td>
<td>4 mg/kg</td>
<td>↓IL-1β, ↓p-Akt, ↓P2Y12 receptor on SGCs in the DRG</td>
<td>83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsicum oleoresin</td>
<td>Nanoemulsion</td>
<td>Obesity</td>
<td>High-fat (HF)-diet-induced obesity in rats</td>
<td>0.1 mL/80 g body weight</td>
<td>20–50 nm</td>
<td>↓Adipogenic gene expression, ↓PPAR-γ, UCP2 and CPT-1α</td>
<td>90</td>
</tr>
<tr>
<td>Alginate double-layer nanoemulsion</td>
<td>Obesity</td>
<td>HF-diet-induced obesity in rats and 3T3-L1 cell line</td>
<td>1,000 ng/mL</td>
<td>↓mRNA levels of PPAR-γ, ↓fatty acid binding protein adipocyte protein-2 hormone-sensitive lipase, ↑carnitine, ↑palmitoyl transferase-Iα, ↑HSL and CPT-1α genes, ↑PPAR-γ and αP2</td>
<td>91</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Phytochemical</th>
<th>Nanoformulation</th>
<th>Disorder</th>
<th>Cellular/animal model</th>
<th>Dose</th>
<th>Size</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berberine</td>
<td>Solid lipid nanoparticles (SLNs)</td>
<td>Diabetes</td>
<td>db/db diabetic mice</td>
<td>100 mg/kg</td>
<td>76.8 nm</td>
<td>↓ Body weight, fasting blood glucose levels, HOMA-IR, ↓ impaired glucose tolerance</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>O-hexadecyl-dextran</td>
<td>High glucose stress induced apoptosis in hepatocytes</td>
<td>Primary hepatocytes cells derived from the liver of Sprague-Dawley rats</td>
<td>0.125 mg to 2.0 mg</td>
<td>238±18 nm</td>
<td>↓ ROS, ↓ Caspase activation, ↓ Oxidative stress</td>
<td>99</td>
</tr>
<tr>
<td></td>
<td>PLGA-PEG-PLGA block copolymers</td>
<td>High LDL cholesterol</td>
<td>Hep-G2 cells</td>
<td>42–63 nm</td>
<td>Modulation of PCSK-9 mRNA</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Naringenin</td>
<td>Alginate-coated chitosan core-shell</td>
<td>Diabetes</td>
<td>STZ-diabetic rats</td>
<td>150–300 nm</td>
<td>No toxicity, better therapeutic effect</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Quercetin</td>
<td>(QUE/P) NP</td>
<td>Diabetic nephropathy</td>
<td>Diabetic rats</td>
<td>10 mg/kg</td>
<td>32 nm</td>
<td>Downregulation of ICAM-1 expression</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>pH sensitive chitosan-alginate core-shell</td>
<td>Diabetes</td>
<td>Human colonic epithelial cell line HT29 and STZ-induced diabetic rats</td>
<td>100 mg/kg</td>
<td>91.58 nm</td>
<td>↓ Serum AST, ALT and ALP levels</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td>PLGA NPs</td>
<td>Diabetes</td>
<td>STZ-induced diabetic rats</td>
<td>150 mg/kg</td>
<td>179.9±11.2 nm</td>
<td>↑ CAT and SOD levels, ↓ Drug doses</td>
<td>116</td>
</tr>
<tr>
<td>Nanoemulsion</td>
<td>Oxaliplatin-induced neuro- and hepatotoxicity</td>
<td>BALB/c mice</td>
<td>20 mg/kg</td>
<td></td>
<td>↓ Inflammation, pain, and apoptosis exploited by oxaliplatin and prevented oxaliplatin-induced neuro- and hepatotoxicity</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Quercetin nanorods</td>
<td>Diabetes</td>
<td>Alloxan-induced diabetic rats</td>
<td>20 mg/kg body weight</td>
<td>15.4 nm</td>
<td>↓ FBG level in blood, ↓ G6Pase and FBPase, ↓ SOD, CAT, GSH, and –SH, ↓ AST, ALP, and ALT</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Emodin</td>
<td>PEGMA-DMAEMA-MAMMAM nanomacromolecule</td>
<td>Diabetic neuropathic pain</td>
<td>T2DM induced by HF diet with low dose of STZ injection in rats</td>
<td>1 mg/mL per rat</td>
<td></td>
<td>↓ Upregulation of TNF-α protein, P2X3 receptor, and the phosphorylation of ERK1/2 in the DRG of T2DM</td>
<td>120</td>
</tr>
<tr>
<td>Nanoemdin transferosome</td>
<td>Antibesity</td>
<td>HF-diet-induced obesity in rats</td>
<td></td>
<td>292.2 nm</td>
<td>Upregulation of ATGL protein expression, downregulation of G0S2 protein expression, body weight, and adipocyte size</td>
<td>121</td>
<td></td>
</tr>
<tr>
<td>Phytochemical</td>
<td>Nanoformulation</td>
<td>Disorder</td>
<td>Cellular/animal model</td>
<td>Dose</td>
<td>Size</td>
<td>Outcome</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>---------</td>
<td>----------------------</td>
<td>------</td>
<td>------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>Gymnemic acid</td>
<td>Nanosuspension</td>
<td>Diabetes</td>
<td>Diabetes-induced rats</td>
<td></td>
<td>92±3.1 nm</td>
<td>↓ Blood glucose levels</td>
<td>124</td>
</tr>
<tr>
<td>Baicalin</td>
<td>Nanostructured lipid carriers</td>
<td>Diabetes</td>
<td>STZ-induced diabetic rats</td>
<td>92±3.1 nm</td>
<td>↓ FBS, HbA1c, and TG levels</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Scutellarin</td>
<td>Amphiphilic chitosan derivatives (Chit-DC-VB12)</td>
<td>Diabetic retinopathy</td>
<td>Caco-2 cells and STZ-induced diabetic rats</td>
<td>150–250 nm</td>
<td>Downregulation of expression of VEGFR2, VEGF, and vWF</td>
<td>132</td>
<td></td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Nanoliposomes</td>
<td>Diabetes mellitus</td>
<td>STZ-induced diabetic cells</td>
<td>30 µg/mL of resveratrol</td>
<td>215 nm</td>
<td>↑ ROS-inactivating enzymes including GSH-Px and SOD</td>
<td>143</td>
</tr>
<tr>
<td>Silybin</td>
<td>PLGA polymers</td>
<td>Systemic hyperglycemia</td>
<td>STZ-induced diabetic rats</td>
<td>215 nm</td>
<td>↑ ROS-inactivating enzymes including GSH-Px and SOD</td>
<td>143</td>
<td></td>
</tr>
<tr>
<td>Myricitrin</td>
<td>SLNs</td>
<td>Diabetes</td>
<td>Hyperglycemic myotube cells and STZ-nicotinamide-induced T2DM mouse</td>
<td>76.1 nm</td>
<td>↑ Improvement of SOD level, ↑ muscle and myotube glycogen content, Glut4 gene expression in skeletal muscle and C2C12 cells, Bcl-2 gene expression, Bax to Bcl-2 ratio of myotubes</td>
<td>153</td>
<td></td>
</tr>
<tr>
<td>Stevioside</td>
<td>Pluronic-F-68 copolymer-based PLA nanoparticles</td>
<td>Diabetes</td>
<td>In vitro release study</td>
<td>10 mg NPs</td>
<td>110–130 nm</td>
<td>↑ Intestinal absorption, bioavailability</td>
<td>156</td>
</tr>
<tr>
<td>α-eleostearic</td>
<td>Bitter Gourd Seed Oil Nanoeulsion</td>
<td>Diabetes mellitus</td>
<td>Alloxan-induced diabetic rats</td>
<td>0.5% and 1%</td>
<td>&lt;100 nm</td>
<td>↑ PPAR-γ</td>
<td>158</td>
</tr>
</tbody>
</table>

**Abbreviations:** PBLG-PEG-PBLG, poly (gamma-benzyl l-glutamate)-poly (ethylene glycol)-poly (gamma-benzyl l-glutamate); H2S, hydrogen sulfide; CNPs @GMs, curcumin nanoparticles@gelatin microspheres; STZ, streptozotocin; SNEDDS, self-emulsifying drug delivery system; PLGA-PVAc, Poly (lactic-co-glycolic acid)-Polyvinyl alcohol; HDL, high-density lipoprotein; SGCs, satellite glial cells; DRG, dorsal root ganglia; HSL, hormone-sensitive lipase; HOMA-IR, homeostasis assessment of insulin resistance; LDL, low-density lipoprotein; QUE/P, Que/poly (ethylene glycol)-block-poly(ethyleneamine l-glutamate)- graft-poly(ε-benzoylcarbonyl-l-lysine)) (PEG-b-(PBLG-g-PZLL)); FBG, fasting blood glucose; TG, triglycerides.
polydispersity index of 0.14±0.06 and nearly 56% curcumin encapsulation. The results demonstrated that curcumin-loaded Poly (lactic-co-glycolic acid) (PLGA) NPs increased efficiency and oral bioavailability in in vivo conditions. In another study, curcumin-loaded pluronic nanomicelles were synthesized and characterized for the treatment of diabetes. Pluronics are triblock copolymers made up from a central block which is made of poly (propylene oxide) and two poly (ethylene oxide) (PEO) chains with the general structure of HO-(C\(_2\)H\(_4\)O)\(_a\)-(C\(_3\)H\(_6\)O)\(_b\)-(C\(_2\)H\(_4\)O)\(_a\))-H. Pluronics have pharmaceutical applications such as emulsifiers, wetting agents, surfactants, and solubilizing agents. Of course, the hydrophilic–lipophilic balance of pluronics may change with the alteration in the numbers of PPO and PEO blocks. Curcumin NPs with a size of 333±6 nm were prepared. Curcumin-loaded pluronic nanomicelles were synthesized via nanoprecipitation method with pluronics. The in vivo experiment was done in an STZ-induced diabetic model. The developed curcumin NPs had antidiabetic action because of the remarkable upregulation of both Pdx-1 and NKx6.1 genes' expression, which are significant transcription factors in insulin gene expression. This formulation was orally delivered and increased the bioavailability of the drug. In another study, PLGA-based NPs encapsulating curcumin and CoQ10 were developed and orally delivered to enhance therapeutic efficacy and oral bioavailability of treatment of diabetic adverse effects. This antioxidation formulation was tested in STZ-induced diabetic rats. The results demonstrated that consumption of these NPs led to a remarkable reduction of CRP, IL-6, total cholesterol, plasma TGs, and an increase in HDL cholesterol. The CoQ10 and curcumin-loaded PLGA NPs were prepared via emulsion-diffusion-evaporation technique. The particle Z-average sizes of curcumin-encapsulated NPs and CoQ10 NPs were 237±6 nm and 115±12, respectively. In another study, a curcumin nanoemulsion was prepared as an antihypercholesterolemic and antihypertensive agent. The potential of curcumin against hypertension was analyzed by measurement of ACE inhibition in an in vitro study. Hippuryl-L-histidyl-L-leucine is a substrate for ACE. The enzymatic process results in the generation of hippuric acid. They demonstrated to what extent curcumin is involved in ACE inhibition by measuring the quantity of hippuric acid production. The antihypercholesterolemic capability was analyzed via HMG-CoA reductase assay. The curcumin nanoemulsion was synthesized using Rasaputri method. The average diameter of curcumin nanoemulsion droplets was 42.93±29.85 nm and the polydispersity index was low and had a value of 0.36±0.04 which was uniform in size. The application of the curcumin nanoemulsion was able to inhibit HMGR along with ACE and also improved curcumin solubility in the formulation. In another study, curcumin-encapsulated NPs were used for treatment of diabetic peripheral neuropathy. Diabetic peripheral neuropathy is a significant and usual consequence of type 2 diabetes that leads to neuropathy. Curcumin-encapsulated NPs were used to relieve diabetic neuropathic pain via P2Y12 receptor on satellite glial cells in the dorsal root ganglia of rat. The NPs diminished the level of Cx43 mRNA in rats, which was the reason for mechanical and thermal hyperalgesia in rats. Also, the level of IL-1β and phosphorylated-AKT decreased in the dorsal root ganglia of diabetic rats after administration of NPs. Furthermore, curcumin NPs reduced the P2Y12 receptor on satellite glial cells in the dorsal root ganglia and thermal/mechanical hyperalgesia in diabetic rats.

For wound healing purposes, one promising method to increase the bioavailability and efficacy of curcumin is the use of hydrogels. Thermos-sensitive hydrogel in the structure of gelatin microspheres containing curcumin was developed for the treatment of diabetic wounds. Curcumin NPs were enclosed in gelatin microspheres to respond to MMPs which are commonly over-expressed at diabetic wound sides. The thermo-responsive hydrogel containing curcumin NPs loaded in gelatin microspheres was used as a local delivery system in the wound site to investigate its capacity for drug release. For temperature responsiveness of hydrogels, pluronic F127 (a type of macromolecular non-ionic surfactant) was applied. F127 demonstrated temperature-dependent gel-sol and sol-gel transition. The synthesized formulation was administered to the genetically and chemically-induced diabetic rats via STZ injection. Thermo-sensitive hydrogel containing curcumin in the form of gelatin microspheres seems an ideal choice as a skin drug delivery system, not only in therapeutics, but also for pharmaceutical and cosmetic products. Various strategies have been developed to overcome the major barriers to the clinical translational use of curcumin. For example, nanoformulation of curcumin has shown therapeutic benefits rather than free curcumin in the management of cancer, cardiovascular, and neurodegenerative diseases. Clinical trials have shown that curcumin nanoformulations improve bioavailability of curcumin, providing a strong rationale for future medical applications after clarification of mechanistic perspectives.

**Capsicum oleoresin**

Oleoresin capsicum has been identified as an organic solvent extract from dried, ripe red pepper, a fruit of the *Capsicum* plant. OC has been extensively used as an additive in the
Naringenin is an option for treatment of cancer. Therefore, for better targeting of the colon and rectum, a new nanoemulsion (OC) was applied in hyperthermia. Quercetin (QUE), a flavonoid found in various foods such as onions, citrus fruits, apples, and tea, has antioxidant and anti-inflammatory activities. It has been reported that administration of QUE decreases inflammation, antiobesity, anti-inflammatory, and anticancer effects. Administration of a nanoemulsion obtained from OC in obese rats decreased adipogenic gene expression and increased expression of PPAR-α, UCP2, and CPT-1α, which participate in thermogenesis and β-oxidation. Administration of this nanoformulation drastically diminished the final body weight and reduced the level of adipose tissue mass in the obese rats which received a high-fat regimen. The antiobesity effect of the nanoemulsion is due to its potential in activation of the AMPK pathway. Activation of AMPK in the rats supplemented with OC nanoemulsion was more dominant than in rats supplemented with OC. The activity of GPDH was also more restricted. However, OC caused no significant effect on the high-fat diet rats, and nanosizing of this extract was the main reason for this high antiobesity activity.

Berberine

Berberine (BBR) is an essential benzylisoquinoline alkaloid from Coptis chinensis. BBR has been employed for treatment of intestinal infections, congestive heart failure, hypertension, cardiac arrhythmia, cancer, hyperlipidemia, and diabetes. Studies have shown that the use of BBR in insulin-resistant animals improves TG levels, body weight, and insulin sensitivity. In fact, BBR upregulates the genes which participate in energy utilization and downregulates the genes which participate in lipogenesis. Its insulin-sensitizing action is similar to that of thiazolidinediones as well as metformin. BBR has been reported to reduce waist circumference, TG levels, and systolic blood pressure. These alterations were found to be more prominent in women suffering from MetS.

Nanoformulated forms of BBR have shown better bioavailability. SLNs containing BBR in comparison to BBR alone have shown higher bioavailability. Oral administration of NPs (BBR-SLN) and bulk formulation of BBR remarkably reduced body weight gain, homeostasis evaluation of insulin resistance, and fasting blood glucose level. O-hexadecyl-dextran encapsulated BBR NPs were prepared and their cytoprotective effects on high glucose stress-induced apoptosis were evaluated in rat primary hepatocytes. Hepatocytes treated with this nanoformulation in high glucose levels of 40 mM, enhanced cells' viability in comparison to bulk BBR treated cells. The results showed a decrease in ROS production, caspase activation, oxidative stress, and prohibition of depolarization of mitochondria in cells treated with NPs. Oral administration of the nanoformulation prepared by PLGA-PEG-PLGA block copolymers containing BBR chloride effectively modulated PCSK-9 mRNA for treatment of high LDL cholesterol.

Naringenin

Naringenin (5,7,4′-trihydroxyflavanone) is part of the class of flavonoids called flavanones which exist in vegetables and citrus fruits like grapefruit and oranges. It has shown antimutagenic, anti-inflammatory, anti-hyperglycemic, and antioxidant activities. Naringenin is an option for treatment of cancer, CVD, and osteoporosis. Also, it reduces levels of lipids and insulin-like characteristics. Regarding the mechanism of action of naringenin, it has been shown to absorb glucose from the intestine of diabetic rats. Naringenin treatment of diabetic mice showed a drastic increase in the immunological and hematological parameters of blood along with 100% survival in diabetic mice. Vasorelaxant impact of naringenin was shown in CVD and hypertension. The main problem of naringenin could be attributed to the fact that it is poorly dissolved in water and poorly absorbed in the intestine after oral administration due to the quick elimination by diverse enzymes located in the gut and liver. Therefore, for better targeting of the colon and modified absorption, nanosizing this flavanone and/or loading it onto NPs, or encapsulating it in a nanoformulation can be considered as practical methods. Core shell NPs (chitosan/alginate) impregnated with naringenin demonstrated no toxicity, with remarkable antidiabetic effects after oral administration in STZ-induced diabetic rats. This polymeric nanoformulation was a biodegradable and biocompatible vehicle for oral transfer of naringenin or other medicaments.

Quercetin

Quercetin (QUE), a flavonoid found in various foods such as onions, citrus fruits, apples, and tea, has antioxidant and anti-inflammatory activities. QUE acts via mitochondrial pathways involved in adipokinesis and lipolysis. It has been reported that administration of QUE decreases...
blood pressure, insulin resistance, and cholesterol.\textsuperscript{108} QUE in combination with other polyphenols such as luteolin and apigenin can increase insulin secretion and resistance to cytotoxicity induced by internal cytokines, decreasing activation of NO synthase and NF-\kappaB.\textsuperscript{81,109–111} QUE has been shown to improve metabolic parameters including postprandial blood glucose, waist circumference, and lipids.\textsuperscript{112}

In a study, poly(ethylene glycol)-block-(poly(ethyleneamine-glutamate)-graft-poly(\varepsilon-phenyloxy(carboxyl-l-lysine))) was prepared and its in vitro and in vivo abilities in the form of nanosized complex with QUE in diabetic nephropathy was examined. The results of blood samples and left kidney analysis demonstrated modified renal function, alleviated renal oxidative stress harm, and downregulated ICAM-1 expression. Also, QUE NPs complex remarkably alleviated the mentioned effects.\textsuperscript{113} A pH sensitive formulation comprising chitosan-alginate core-shell NPs loaded with succinylated-QUE NPs demonstrated no in vivo toxicity as biocompatible and biodegradable carriers for oral administration of QUE.\textsuperscript{114} QUE (20 mg/kg) in combination with other antioxidants including rutin (20 mg/kg) and resveratrol (100 mg/kg), and QUE nanoemulsion (20 mg/kg) demonstrated positive outcomes in decreasing inflammation, pain, and apoptosis exploited by oxaliplatin, and prevented oxaliplatin-induced neuro- and hepato-toxicity in mice.\textsuperscript{115}

Similar to other compounds, nanoformulations of QUE possess a higher bioavailability in comparison with formulations in larger scales. Loading QUE on PLGA via emulsion-diffusion-evaporation technique was one of the attempts to increase the bioavailability of QUE and decrease the dosage required for treatment. The oral bioavailability of this nanoformulation in rats was more than 52.3% and it caused a required drug dose because of nanosizing QUE. These results clearly highlighted the importance of oral administration of QUE NPs in a reduced dose for treatment of diabetes.\textsuperscript{116} In another study, QUE nanorods (15.4 nm) were synthesized and their effect was tested on alloxan-induced diabetic rats. Administration of this type of NPs decreased the level of fasting blood glucose in diabetic mice. QUE decreased generation of lipid peroxidation products. The activity of hexokinase, as a primary enzyme in glycolysis pathway, was diminished in diabetic samples including kidney, pancreas, and liver. The activity of G6Pase was remarkably diminished upon using QUE nanorods. Also, the activity of FBPase, an enzyme of gluconeogenesis pathway, was decreased with the application of nanorods. This nanoformulation enhanced the level of antioxidant enzyme SOD, GSH, and thiol groups, and diminished protein oxidation and lipid peroxidation in diabetic mice. Furthermore, the kidney and liver functional markers including ALP, ALT, and AST were decreased. The rod structure was an efficient structure for treatment of diabetes, but further studies in the field are still required.\textsuperscript{117} PLGA-loaded QUE NPs with a particle size of 180 nm increased the bioavailability in STZ-induced diabetic rat model. This gives hope for the development of different QUE-based nanocarriers to improve oral delivery and for future medicine with lower carrier toxicities for diabetic patients.\textsuperscript{106}

**Emodin**

Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an anthra-quinone derivative, which can be found in Radix et rhizoma rhei.\textsuperscript{118} Emodin possesses anti-inflammatory, antinociceptive, and anticancer activities.\textsuperscript{119} Emodin has PPAR-\gamma-activating impacts. Intraperitoneal injections of this compound alleviated the symptoms of diabetes via regulating PPAR-\gamma. Emodin increased binding affinity in differentiated 3T3-L1 adipocytes via induction of enhanced glucose uptake and enhanced GLUT1 and GLUT4 mRNA expression. Furthermore, emodin is a novel activator of AMPK and had positive impact on glucose metabolism in 3T3-L1 adipocytes through enhancement of glycolysis.\textsuperscript{119} Nanomacromolecule encapsulating emodin was used for treatment of diabetic neuropathic pain. This nanoformulation had the effect on P2X3 receptor located on the dorsal root ganglia. Mechanical withdrawal threshold and thermal withdrawal latency in rats receiving emodin NPs were greater in comparison with those in diabetic rats. This nanosolution diminished upregulation of TNF-\alpha protein, P2X3 receptor, and the phosphorylation of ERK1/2 in the dorsal root ganglia of rats suffering from type 2 diabetes. Emodin-loaded nanomacromolecules could alleviate neuropathy via prohibiting excitatory transmission induced by P2X3 receptor in dorsal root ganglia neurons.\textsuperscript{120} Another nanoformulation called nano emodin transferosome (NET) was prepared, and mRNA expression of ATGL and G0S2 in adipose tissue of obese rats were investigated. NET could increase ATGL protein expression to apply its weight-reduction impact and decreased G0S2 protein expression in the adipose tissue of obese rats. NET diminished body weight and adipocyte size.\textsuperscript{121} Emodin has shown high first pass metabolism and great hydrophobicity associated with a limited bioavailability after oral administration. Hence, nanoemulsions and nanotransfers have been effective in better delivery and efficiency of emodin.\textsuperscript{106}

**Gymnemic acid**

Gymnemic acid (C_{43}H_{66}O_{14}) is a triterpenoid phytoconstituent of Gymnema sylvestre, possessing a strong antidiabetic effect.\textsuperscript{122}
Gymnemic acid has presented diverse physiological activities such as suppressing taste sensitivity to sweetness, preventing intestinal absorption of glucose, and decreasing the level of glucose and insulin in plasma of diabetic patients. The poor water solubility of this phytochemical decreases its pharmacological effects. Thus, a modified approach is needed to enhance the bioavailability and solubility of gymnemic acid. In a study, a nanosuspension of gymnemic acid was prepared and the oral nanoformulation tested on diabetic rats. The nanoformulation demonstrated meaningful antihyperglycemic activity and generated hypoglycemia. Gymnemic acid nanoformulations could reduce blood glucose levels in diabetic rats after 3 hours. It seems that gymnemic acid nanoformulation can be an efficient option for treatment of diabetes.

Baicalin
Baicalin (5,6-dihydroxy-2-phenyl-4H-1-benzopyran-4-one-7-O-β-glucuronic acid) is one of the principal flavonoids of Scutellaria radix. Like other flavonoid extracts, baicalin possesses anti-inflammatory properties via scavenging ROS and causes antioxidant modification by decreasing the activity of NF-κB. It also suppresses the expression of lots of inflammatory cytokines and chemokines such as MCP-1, cyclooxygenases, nitric oxide synthase, tumor necrosis factor, interleukins, and lipooxygenases. Thus, it is considered a promising choice for alleviating diabetes and relevant disorders like CVDs, gout, inflammatory bowel disease, and neurodegeneration. Baicalin possesses low hydrophilicity and is poorly absorbed after oral administration because of its glycosylc group. The nanoformulation form was established by loading baicalin onto lipid carriers, and evaluated for antidiabetic activity. The in vivo study was done on STZ-induced diabetic male Sprague-Dawley rats. The results demonstrated that baicalin and its nanoformulated form remarkably diminished the TC, HbA1c, and TG levels, providing a hypoglycemic effect with regulation of lipid metabolism in diabetic rats. Various nanosized formulations of baicalin such as NPs, liposomes, and nanoemulsions have been used to improve its bioavailability. When the oral bioavailability of regular baicalin crystals and baicalin solid nanocrystals was examined in rats, a remarkably better result was shown. Recently, nanosuspension has been applied to resolve the formulation problem of scarcely soluble drugs.

Scutellarin
Scutellarin (4′,5,6-trihydroxyflavone-7-O-glucuronide), one of the most active compounds of the traditional Chinese herb Erigeron breviscapus (Vant.) Hand. Mazz., has been frequently used against vascular endothelial cell dysfunction; it exerts its effect via many pathways. Experimental research and clinical observation demonstrated that scutellarin possesses a powerful effect against neovascularization and enhances vascular permeability via diminishing viscosity of blood flow and improving microcirculation. A nanoformulation based on scutellarin loaded onto amphiphilic chitosan derivatives was prepared to increase its bioavailability and efficacy for treatment of diabetic retinopathy. The synthesized particles demonstrated great capacity to be transferred from Caco-2 cells. Results indicated that administration of scutellarin diminishes retinal damage in diabetic rats. Treatment with the nanoformulation was more efficient than the scutellarin alone. Scutellarin resulted in downregulated expression of VEGFR2, VEGF, and vWF in the retina of diabetic rats. The scutellarin nanostructure enhanced the bioavailability of scutellarin and significantly improved diabetic retinopathy.

Resveratrol
Resveratrol (3,5,4-trihydroxystilbene) is a polyphenol found in grapes and nuts that has extensive pharmacological activities including anti-inflammatory, strong antioxidant, antiplatelet, analgesic, neuroprotective, cardioprotective, and antiaging. It remarkably modifies glucose metabolism and oxidative injury. Resveratrol has been shown to activate the sirtuin pathway. Different cellular functions, which are linked to oxidation, metabolism, and aging are regulated by the sirtuin pathway. Resveratrol affects cellular energy homeostasis, increases lipolysis, activates Nrf2, decreases adipogenesis and blood cholesterol, inhibits cyclooxygenase, and protects cardiac cells. Resveratrol has been shown to promisingly enhance insulin sensitivity, glucose tolerance, and decrease weight and body mass index in patients suffering from MetS. Resveratrol affects cellular energy homeostasis, increases lipolysis, activates Nrf2, decreases adipogenesis and blood cholesterol, inhibits cyclooxygenase, and protects cardiac cells. Resveratrol has been shown to promisingly enhance insulin sensitivity, glucose tolerance, and decrease weight and body mass index in patients suffering from MetS. Resveratrol seems a promising adjuvant therapy for management of type 2 diabetes. Studies demonstrated that treatment with resveratrol exhibits antidiabetic potential in pancreatic cells via diminishing hyperglycemia, preservation of cells, enhancing insulin secretion, and antioxidant effect. Resveratrol-loaded nanoliposomes were prepared for alleviation of diabetes in STZ-induced diabetic animals. The liposomes were PEGylated covalently to increase plasma half-life and residence time of the nanoliposome loaded with resveratrol. The results demonstrated that liposomes enhanced the expression of ROS-inactivating enzymes such as GSH-Px and SOD with extended release of resveratrol in diabetic pancreatic β TC cells. This nanoformulation loaded with
resveratrol could be an advantageous formulation for treatment of and protection against type 2 diabetes mellitus.\textsuperscript{143} Another formulation including resveratrol (resveratrol-loaded nanocapsules) was synthesized and the effect of this nanoformulation was investigated on mice with MetS. The results illustrated that the systolic and diastolic blood pressures were regulated in mice treated with nanocapsules.\textsuperscript{144} The management of diabetes with resveratrol has been challenged due to small cohorts of patients and short duration of trials, low bioavailability of RSV in humans due to rapid glucuronation, sulfation and clearance from the body. Many bioavailability studies are vague in quantifying tissue distribution and plasma bioavailability of RSV pool. Therefore, the dosage required for optimal bioavailability for sufficient tissue distribution needs to be clarified.\textsuperscript{145} New approaches to increase the bioavailability may help to actualize its potential as therapeutic agent in diabetes and related complications. The use of resveratrol or its analog could be combined with nanotechnology to treat or prevent human diabetes in the near future.

Silybin
Silybin is the main active ingredient, accounting for 34\% of total mass, of silymarin. Silybins A and B are the most common diastereoisomers. The plant is mostly found in Southern Europe and Asia.\textsuperscript{145} This compound possesses low toxicity and exhibits remarkable hepatoprotective, anti-inflammatory, and anticarcinogenic effects. Silybin has been shown to be effective in obesity-induced insulin resistance related to its anti-inflammatory and fat reduction properties.\textsuperscript{146} Furthermore, the results of experiments demonstrated that silymarin remarkably diminished epidermal fat mass and body weight with unchanged food intake.\textsuperscript{146–148} In another study, PLGA polymers loaded with silybin were prepared and the effect of this nanoformulation was tested on STZ-induced rats. The loading efficiency of silybin was more than 92.11\%. The results showed that this nanoformulation contributed to diabetes control and reduced hyperglycemia. Silybin is associated with powerful antioxidant characteristics, regenerative impacts on beta cells, and increased membrane permeability. This nanoformulation introduced a new approach for the control of diabetes and has been used as a coadjuvant in therapy.\textsuperscript{149}

Myricitrin
Myricitrin (myricetin-3-O-α-rhamnoside) is an herbal flavonol glycoside extracted from some plants (\textit{Pouteria gender}, \textit{Myrica rubra}, \textit{Manilkara zapota}, and \textit{Eugenia uniflora}).\textsuperscript{150} Myricitrin possesses anti-nociceptive, anxiolytic, antioxidant, and anti-inflammatory effects. Due to its high antioxidant activity, it is considered as an essential supplement in medicine. Research has revealed that myricitrin prevents vein endothelial cell dysfunction caused by ROS via diminishing H\textsubscript{2}O\textsubscript{2}-induced oxidative damage, reducing malondialdehyde, and regulation of activity of antioxidant enzymes.\textsuperscript{151} The metabolism and bioavailability of flavonoids, especially flavonoid glycosides, are the essential characteristics that should be considered. Due to high polarity it is not able to cross membranes.\textsuperscript{152} SLNs containing myricitrin showed protective impact against cytotoxicity induced by STZ in β-cells. In addition, antioxidant and antidiabetic effects of SLNs containing myricitrin were reported in a STZ-nicotinamide-induced diabetic model and myotube cell of a male mouse.\textsuperscript{153}

Stevioside
Stevioside can be extracted from the leaves of \textit{Stevia rebaudiana} (Bertoni), known to have powerful antidiabetic activity.\textsuperscript{154} Research has demonstrated that stevioside has an impact on renal function and glucose metabolism.\textsuperscript{155} Stevioside has the ability to regulate the concentration of glucose in blood via boosting insulin utilization and insulin secretion in rats with insulin deficiency. Stevioside has been proven as one of the powerful antidiabetic agents, but it possesses less therapeutic efficiency because it is poorly absorbed in the intestine, and has scarce bioavailability. Poly-lactic acid (PLA) NPs based on Pluronic-F-68 copolymer containing stevioside were synthesized and evaluated in diabetes. The particle size of the synthesized nanoformulation was 110–130 nm with a spherical structure. Stevioside efficiently incorporated in NPs increased the bioavailability and intestinal absorption. The nanocapsulation of stevioside in PLA showed better drug release and more absorption in the intestine compared to free stevioside.\textsuperscript{156} Due to the presence of highly bioactive molecules, \textit{S. rebaudiana} is now employed in several commercial formulations.

Alpha-eleostearic acid
Bitter ground oil (BGO) contains approximately 30\%–50\% α-eleostearic acid, which possesses antioxidative and ROS-scavenging effects.\textsuperscript{157} Conjugated linolenic acid isomers increase immunity and behave as anti-adipogenic and anti-inflammatory agents.\textsuperscript{15} In a study, a bitter ground seed oil
nanoemulsion was synthesized to enhance bioavailability of conjugated linolenic acid in an in vivo system undergoing oxidative stress. For the in vivo study, rats were divided into five groups. Group A was only administered sunflower oil; group B was orally administered sunflower oil diet and intraperitoneally alloxan; group C received alloxan intraperitoneally and sunflower oil orally: nanoemulsion (99.5: 0.5 v/v) containing 0.25% conjugated linolenic acid once a day; received alloxan intraperitoneally and BGO nanoemulsion with sunflower oil orally: nanoemulsion (99: 1 v/v) containing 0.5% conjugated linolenic acid; the diet of group E was similar to that of group C, but the conventional emulsion of BGO was used; the diet of group F was similar to that of group D, but the conventional emulsion of BGO was used. According to results, the concentration of blood glucose decreased after administration of 0.5% and 1% nanoemulsion which contained 0.25% and 0.5% α-eleostearic acid, respectively. α–eleostearic acid upregulated PPAR-γ and modified insulin sensitivity and thus glucose tolerance. The remarkable improvement was in the antioxidative enzymes including GPx, SOD, and CAT in the liver and plasma fractions. This nanoemulsion system ameliorated the stress state induced by alloxan via antioxidative defense. This research showed the possibility of application of conjugated linolenic acid as a powerful nutraceutical for further usage. Advanced studies on engineered nanomaterials have shown that NPs interact with the biological interfaces on a more targeted level than conventional therapeutics. Hence, it is of pivotal importance to explore the interactions at a biological interface, bringing them into practice for biomedical purposes.

Translational insights and future perspective of nanoformulations for MetS

Most studies on MetS and obesity have been conducted on the peripheral organs, while the role of the central nervous system has been poorly recognized. Improvement of the sympathetic system activity has positive roles in MetS and conditions such as obesity, hypertension, insulin resistance, dyslipidemia, and inflammation. For instance, leptin is responsible for increasing sympathetic renal activity and affects oxidative stress elements. Also, the role of inflammation in different determinants of MetS has been described. Adipokines are known to induce insulin resistance and atherosclerosis through specific elements such as adiponectin, TNF-α, IL-6, MCP-1, and leptin. If it is postulated that obesity is a multi-component disease, the impairment of vascular function is observed in almost all subjects. Therefore, further focus on the role players of MetS in the central nervous system along with vascular dysfunction and inflammatory elements is necessary. Literature review shows that natural products can affect the previously mentioned mechanisms of MetS in a positive way. Thus, good and efficient delivery to the human body is a necessity. Biodegradable NPs have been found useful for the delivery of proteins and peptides in minimum doses, and studies on the natural products continue. The final goal should be to carry and deliver the medicine to the target site of action with enough understanding of the mechanisms involved in MetS. Unfortunately, discovery and development of potent drugs against MetS have been greatly hampered due to lack of a suitable preclinical model. Meanwhile, several studies are still warranted to find and screen new readily available plants, isolate their active compounds, and test pharmacological activities. The safety of nanoformulations fabricated from herbal-based compounds is another concern that must be taken into account. Focusing on the “antidiabetic” activity of plants rather than their “hypoglycemic” effect would be of high priority because of further clinical implications in MetS. It seems that there is no well-developed approach to test these compounds, especially details of lipid metabolism, thus future studies will possibly consider this limitation. Nanoformulations based on natural products should be biodegradable, biocompatible, nontoxic, and in the meantime should have a great ability to enter cells and produce a rapid action, and be stable after oral administration. Risk benefit and cost effectiveness are further concerns that have to be noted. Justification of the efficacy of these novel therapies remains to be established by conducting precise clinical trials.

Conclusion

MetS is a complex of disorders including mainly impaired glucose tolerance, insulin resistance, and hyperinsulinemia. It has been shown that natural-based compounds or their derivatives are great sources for therapeutic applications, especially in diabetes and its complications and in inflammatory pathways mediated through insulin resistance in MetS. Plant-based natural products improve obesity-associated MetS such as hyperglycemia, hyperlipidemia, and insulin resistance, reduce systolic and diastolic blood pressure, and reduce body weight gain. The mechanism of effect of these phytochemicals has been schematically summarized in Figure 1. These compounds were found to suppress expression of PAI-1, downregulate ICAM-1 expression, regulate COX-1 and -2, downregulate TNF-α expression, suppress
NF-κB activation, activate PPARs, and inhibit P2X3 receptor activity and the phosphorylation of ERK1/2 in the dorsal root ganglia. The low oral bioavailability of these phytochemicals is considered as an obstacle to achieve the highest therapeutic efficacy from these compounds. In order to improve the bioactivity and functionality of these products, and also for

Figure 1 A schematic diagram of the mechanism of action of different phytochemicals against metabolic syndrome.
better targeting of colun and modified absorption, nanosizing or loading of NPs, or encapsulating in nanoformulation can be considered as practical methods.

Encapsulation in multipolymer NPS, nanoemulsions, and solid lipid nanoformulations, and using SEDDs, nanoliposomes, and nanosuspensions are some of the methods for enhancing solubility and bioavailability, increasing plasma half-life, and eventually improving the efficacy of these natural compounds in management of MetS.

Although the published reports have shown that these nanoformulations can be good candidates for adjunctive therapy for MetS, further clinical studies are required to explore the therapeutic benefits of nanoformulations in direct comparative studies with unformulated, approved therapeutics. Cost effectiveness studies are highly recommended, particularly for the well established nanoformulations.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


International Journal of Nanomedicine
Publish your work in this journal
The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.